352 articles about NovoCure Ltd.
Quarterly net revenues of $134.7 million with 80% gross margin Interim analysis for phase 3 pivotal LUNAR trial in non-small cell lung cancer concluded with favorable recommendation to continue the trial with reduced sample size
Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR trial DMC stated accrual to 534 patients is likely unnecessary and possibly unethical for patients randomized to control arm and recommended a shortened trial
Novocure Announces 26 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields
Novocure (NASDAQ: NVCR) today announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10 to April 15, 2021.
Novocure announced that it will report financial results for the first quarter 2021 on Thursday, April 29, 2021, before the U.S. financial markets open.
Quarterly net revenues of $144.0 million, representing 45 percent growth versus the fourth quarter 2019 and 9 percent growth versus the third quarter 2020
Timothy J. Scannell, President and Chief Operating Officer of Stryker Corporation, elected to board of directors.
Novocure Announces Fourth Quarter and Full Year 2020 Preliminary Net Revenues and Provides Company Update
Full year 2020 preliminary net revenues of $494.4 million, representing annual growth of 41 percent compared to 2019
Novocure (NASDAQ: NVCR) will participate virtually in the 39 th Annual J.P. Morgan Healthcare Conference on January 11 through January 14, 2021. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 8:20 a.m. EST on January 12, 2021. Management will also participate in
Novocure Announces National Reimbursement in Switzerland for Optune® in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
Novocure announced that the Swiss Federal Office of Public Health has added Optune in combination with temozolomide to the List of Remedies and Equipment for the treatment of patients with newly diagnosed glioblastoma, effective April 1, 2021.
Novocure Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual Meeting
Presentations on Tumor Treating Fields cover a broad and growing range of topics, with nearly 85 percent of presentations prepared by external authors
The application of CE mark enables Novocure to commercialize the NovoTTF-100L System as a treatment for Malignant Pleural Mesothelioma in the European Union and Switzerland
Event will review two decades of Tumor Treating Fields research and introduce exciting new directions of ongoing research and development
Novocure Announces Closing of $150 Million Revolving Credit Facility with a Syndicate of Relationship Banks
Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, today announced the closing of a new $150 million senior secured revolving credit facility with JPMorgan Chase Bank, N.A. as administrative agent and a syndicate of three relationship banks.
Novocure announced the closing of its previously announced offering of $575 million aggregate principal amount of its 0% Convertible Senior Notes due 2025, which includes the exercise in full by the initial purchasers of their option to purchase an additional $75 million aggregate principal amount of notes, in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
Novocure, a global oncology company striving to extend survival in some of the most aggressive forms of cancer, announced the pricing of $500 million aggregate principal amount of its 0% Convertible Senior Notes due 2025 through a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
Novocure (NASDAQ: NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced its intention to offer $500 million aggregate principal amount of Convertible Senior Notes due 2025 (the “notes”). The notes will be offered in a private placement (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended
Quarterly net revenues of $132.7 million, representing 44 percent growth versus the third quarter 2019 and 14 percent growth versus the second quarter 2020
Novocure Announces Strategic Alliance with NYU Grossman School of Medicine for Preclinical and Clinical Research
Novocure announced it has entered into a strategic alliance with the NYU Grossman School of Medicine’s Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields.
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2020 on Thursday, October 29, 2020, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the three and nine months ended September 30, 2020, at 8 a.m. EDT on Thursday, October 29, 2020. Analysts and investors can participate in the conf
Novocure’s virtual Research & Development Day on November 12 will highlight progress across clinical and developmental pipelines and introduce areas of focus in translational research ST. HELIER, Jersey--( BUSINESS WIRE )-- Novocure (NASDAQ: NVCR) announced today that it will host a virtual Research & Development Day for analysts and investors from 7:30 a.m. to 9:30 a.m. EDT on Thursday, November 12, 2020, to highlight progress across its clin